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ABSTRACT
Acinetobacter remains one of the most chal-
lenging pathogens in the field of infectious
diseases owing primarily to the uniqueness and
multiplicity of its resistance mechanisms. This
resistance often leads to devastatingly long
delays in time to appropriate therapy and
increased mortality for patients afflicted with
Acinetobacter infections. Selecting appropriate
empiric and definitive antibacterial therapy for
Acinetobacter is further complicated by the lack
of reliability in commercial antimicrobial sus-
ceptibility testing devices and limited break-
point interpretations for available agents.
Existing treatment options for infections due to
Acinetobacter are limited by a lack of robust
efficacy and safety data along with concerns
regarding appropriate dosing, pharmacokinetic/
pharmacodynamic targets, and toxicity.
Antimicrobial stewardship programs are essen-
tial to combat this unpredictable pathogen
through use of infection prevention, rapid
diagnostics, antibiogram-optimized treatment
regimens, and avoidance of overuse of antimi-
crobials. The drug development pipeline
includes several agents with encouraging
in vitro activity against Acinetobacter, but their
place in therapy and contribution to the arma-
mentarium against this pathogen remain to be
defined. The objective of this review is to
highlight the unique challenge of treating
infections due to Acinetobacter and summarize
recent literature regarding optimal antimicro-
bial treatment for this pathogen. The drug
development pipeline is also explored for future
potentially effective treatment options.
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Infections due to antibiotic-resistant bacteria
are responsible for significant morbidity, mor-
tality, and excess healthcare costs [1]. Of these
resistant organisms, Acinetobacter remains one
of the most formidable opponents, as its unique
and eclectic resistance mechanisms allow it to
escape the activity of the majority of our cur-
rently available antimicrobials. This pathogen is
a member of the ESKAPE [Enterococcus faecium,
Staphylococcus aureus, Klebsiella pneumoniae,
Acinetobacter baumannii (AB), Pseudomonas
aeruginosa, and Enterobacter spp.] group which
have been highlighted for their resistance and
association with negative clinical outcomes [2].
The mortality rate due to multidrug-resistant
(MDR; i.e. non-susceptibility to at least one
agent in three or more antimicrobial categories)
[3] healthcare-associated AB alone is approxi-
mately 10.6%, with an estimated cost per
infection ranging from US$33,510 to $129,917
[4]. So-called ‘‘superbugs’’ like MDR Acinetobac-
ter undermine decades of advances made in
medicine, surgery, and transplantation. The
acquisition of resistance mechanisms is
increasing in frequency among this pathogen
[5], leading to extensively (XDR; i.e. non-sus-
ceptibility to at least one agent in all but two or
fewer antimicrobial categories) [3] resistant iso-
lates and threatening the effectiveness of our
remaining antibiotics, including those used as
last-resort therapeutic options. This resistance
poses significant challenges when selecting
empiric antibiotic therapy and often leads to
devastatingly long delays in time to appropriate
therapy. While these delays undoubtedly lead
to increases in mortality [6, 7], knowledge of
local susceptibilities and application of antimi-
crobial stewardship practices can work to
improve outcomes.
Few currently available and pipeline agents
have reliable activity against Acinetobacter. As a
result, clinicians are forced to resort to older
agents with more narrow therapeutic windows
and a paucity of modern efficacy data to support
their use, including the polymyxins, tetracycli-
nes, and the aminoglycosides. This review will
discuss the challenge of treating infections due
to Acinetobacter and summarize recent literature
regarding optimal antimicrobial treatment. We
will also explore the horizon for antimicrobials
in the development pipeline with activity
against this pathogen. This article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
MICROBIOLOGY
AND PATHOGENICITY
Bacteria within the genus Acinetobacter are
ubiquitous, encapsulated, non-lactose fermen-
tative, oxidase-negative Gram-negative coc-
cobacilli. The vast majority of infections are
caused by the Acinetobacter calcoaceticus–bau-
mannii complex, which is comprised of A. cal-
coaceticus, A. baumannii, A. nosocomialis, and A.
pittii, with A. baumannnii (AB) being the most
clinically important species responsible for the
highest incidence of MDR and mortality com-
pared to other Acinetobacter species [8]. AB may
survive on wet or dry inanimate surfaces for up
to 4 months [9], and can colonize patients for
up to 42 months, which may contribute to its
endemicity and proclivity for outbreaks [10].
Acquisition and spread of AB has been noted
particularly in long-term care and skilled nurs-
ing facilities.
The exact reason for the success of the
Acinetobacter spp. is largely unknown. Although
its name is loosely derived from the Greek word
akineto, meaning ‘‘non-motile’’, AB actually
possesses several core motility genes which can
assemble pilli and produce motility under cer-
tain conditions, and may contribute to its abil-
ity to spread on fomites and form biofilms [11].
AB specifically possesses several features that
may enhance its survival, including simple
growth requirements and resistance to the nat-
ural bactericidal activity of human complement
[12]. Acinetobacter has the ability to acquire and
rearrange genetic material, leading to new and
enhanced virulence and antimicrobial resis-
tance. Its virulence mechanisms are not well
understood, but include its outer membrane
porins, surface capsules and lipopolysaccharide,
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iron acquisition systems, and regulatory pro-
teins. The implication of these mechanisms in
disease transmission and pathogenicity have
been reviewed in detail elsewhere [8].
AB primarily causes nosocomial infections,
although community-acquired infections have
been reported [13] and are increasing nationally
and internationally [14–16]. Globally, the inci-
dence of MDR AB exceeds 75% in Africa, Asia,
and Latin America and 90% in parts of Europe
and the Middle East [17]. In the U.S., car-
bapenem-resistant AB (CRAB) increased from
9% in 1995 to 40% in 2004 [18]. A 2011 survey
of 11 Latin American countries found that more
than 50% of AB were carbapenem-resistant [19]
compared to rates as high as 85% in Turkey,
Greece, Italy, Spain, and England [20]. Pneu-
monia is the most common AB infection, and
the majority (57.6%) of AB isolates in the U.S.
are cultured from the respiratory tract, followed
by the bloodstream (23.9%), and skin and soft
tissue (9.1%) [21]. AB is the fifth leading cause
of ventilator-associated pneumonia (VAP) and
13th of central line-associated bloodstream
infections [22]. Risk factors for AB infection
include prolonged hospital/ICU stay, immuno-
suppression, invasive devices and procedures,
mechanical ventilation, and broad-spectrum
antibiotic exposure [18]. AB infections tend to
occur in vulnerable, debilitated patients
including those in ICUs and residents of long-
term care facilities, especially those who are
ventilator-dependent. The mortality rate for
these serious infections due to AB varies by
geography and type of infection, but is roughly
30–75%.
MECHANISMS OF RESISTANCE
In the 1970s, AB was routinely susceptible to
ampicillin and cephalosporins. By the 1990s,
resistance to carbapenems had emerged and
current reports describe strains resistant to all
available antimicrobials, including colistin,
polymyxin B, and tigecycline [23]. This in vitro
resistance has been associated with negative
clinical outcomes including increased ICU
length of stay and mortality [8]. Table 1 pro-
vides a summary of commonly identified
mechanisms of resistance in AB. Compared to
other Gram-negative pathogens, the ability to
and ease with which AB acquires new resistance
mechanisms via plasmids, transposons, and
integrons is quite remarkable. AB employs a
myriad of resistance mechanisms, including
enzymatic hydrolysis, target site alterations,
porin loss, and efflux pumps. In contrast to
many other Gram-negative species, these
mechanisms are often employed in combina-
tion in MDR AB isolates [24].
Ambler class A extended spectrum b-lacta-
mase (ESBL) enzymes are becoming increasingly
common in non-fermenting Gram-negative
pathogens like AB. The most common are the
PER-, VEB- and GES-types [24]. These enzymes
have been identified throughout the world, with
PER-1 being the most common in the U.S. The
next most common ESBL in AB, the Vietnamese
ESBL (VEB), shares only 38% amino acid identity
with PER-1, speaking to the diversity and chal-
lengingnature of AB resistancemechanisms [25].
Additionally, GES-type ESBLs, which possess
amplified hydrolytic activity towards aztreonam
and ceftazidime, have been increasingly reported
in AB since 2010 [26]. Conversely, commonESBL
enzymes found in Enterobacteriaeceae, like
TEM-, SHV-, and CTX-M-types, have rarely been
identified in AB and may be due to limited hori-
zontal gene transfer as a result of narrow-spec-
trum plasmid replication properties [24]. Unlike
Enterobacteriaceae spp., KPC enzymes have
rarely been identified in AB and are not a major
player in its resistance armamentarium.
Class B metallo-b-lactamase enzymes have
also been identified in AB with increasing fre-
quency, including IMP-, VIM-, SIM-, and
NDM-type enzymes. These zinc-based enzymes
confer resistance to b-lactams and carbapenems,
and are not inhibited by clinically available
b-lactamase inhibitors [27]. At least 9 different
IMP varieties have been identified in AB around
the world [28–32], while the Seoul imipenemase
(SIM-1) carbapenemase has to date been repor-
ted only in South Korea and China [33, 34].
NDM-1 and NDM-2 have also been reported in
AB, primarily in China, Europe, Africa, and the
Middle East [35].
One of AB’s primary mechanisms of resis-
tance to commonly utilized first-line
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antimicrobials are Class C b-lactamases. A wide
variety of AmpC-type cephalosporinases have
been identified in AB and subsequently named
Acinetobacter-derived cephalosporinase (ADC)
enzymes. Importantly, some of these ADC
variants such as ADC-33 and ADC-56 have
extended spectrums which allow them to
hydrolyze cefepime, whereas wild-type AmpC
such as those often found in Enterobacteriaceae
do not [36, 37].
Class D b-lactamase production, primarily of
the OXA-type, exhibit low-level carbapenemase
activity and are only weakly expressed in most
AB isolates. Overexpression can occur and lead
Table 1 Common mechanisms of resistance in Acinetobacter baumannii










TEM Acquired serine b-lactamase Penicillins, cephalosporins, monobactams, sulbactam
IMP Acquired metallo-b-lactamase Penicillins, cephalosporins, carbapenems, b-lactamase inhibitors
SIM Acquired metallo-b-lactamase Penicillins, cephalosporins, carbapenems, b-lactamase inhibitors
NDM Acquired metallo-b-lactamase Penicillins, cephalosporins, carbapenems, b-lactamase inhibitors
ADC Intrinsic AmpC b-lactamase Aminopenicillins, oxyiminocephalosporins, cephamycins,
b-lactamase inhibitors
-ADC-33 Intrinsic AmpC b-lactamase Aminopenicillins, oxyiminocephalosporins, cephamycins, cefepime,
b-lactamase inhibitors
-ADC-56 Intrinsic AmpC b-lactamase Aminopenicillins, oxyiminocephalosporins, cephamycins, cefepime,
b-lactamase inhibitors
OXA Intrinsic serine carbapenemase Oxacillin, clavulanate, sulbactam, tazobactam
AdeABC Resistance-nodulation-cell division
efﬂux pump
Aminoglycosides, ﬂuoroquinolones, tetracyclines, trimethoprim
Tet Efﬂux pump Tetracyclines, tigecycline





Loss of LPS production Polymyxins
ArmA 16S RNA methyltransferase Aminoglycosides
GyrA DNA gyrase alterations Fluoroquinolones
ParC DNA topoisomerase IV alterations Fluoroquinolones
RpoB RNA polymerase alterations Rifampin
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to carbapenem nonsusceptibility when com-
bined with other mechanisms. The OXA-23
enzyme is the most widespread and has been
identified on all inhabited continents [27].
AB has also demonstrated the ability to confer
resistance to aminoglycosides, fluoroquinolones,
tetracyclines, and trimethoprim through com-
plex efflux systems such as the resistance-nodu-
lation-cell division system [38, 39]. Tigecycline
maintains in vitro activity against AB, and the
mechanisms of resistance in cases of resistant
isolates is likely due to effluxpumps. Resistance to
colistin has been described and is commonly due
to either alterations of the lipid A component of
the lipopolysaccharide (LPS) [40] or complete loss
of LPS production [41], although diversity among
polymyxin resistancemechanisms isbeginning to
be described [42].
Worldwide, less than 30% of AB are fluoro-
quinolone-susceptible [17], due to mutations in
the quinolone resistance determining regions of
gyrA and parC genes and/or overexpression of
efflux pumps [12]. Resistance to aminoglyco-
sides exceeds 60% in most countries and is due
primarily to production of aminogly-
coside-modifying enzymes like ArmA, or efflux
pumps. The major mechanism underlying
rifampin resistance is substitution of amino
acids in the target protein, commonly occurring
through a single mutation to the rpoB gene.
ANTIMICROBIAL SUSCEPTIBILITY
TESTING
Laboratories in the U.S. have reached a critical
juncture in their ability to perform antimicro-
bial susceptibility testing (AST) as a result of
regulatory changes that limit test menus of
commercial AST devices (cASTs). These changes
drastically limit the ability to test Acinetobacter
spp., a genus for which antibiotic susceptibility
is rarely predictable. As such, timely and accu-
rate AST of Acinetobacter isolates is critical to the
management of patients. In the U.S., two orga-
nizations establish breakpoints—the Clinical
and Laboratory Standards Institute (CLSI) and
the U.S. Food and Drug Administration (FDA).
The vast majority of U.S. laboratories perform
susceptibility testing using cASTs, which are
regulated by the FDA; by U.S. law, cASTs must
use FDA breakpoints. This presents a major
challenge for Acinetobacter spp., as FDA only
grants breakpoints for those organisms against
which a given antibiotic has proven activity,
both in vitro and in clinical infections (i.e.,
organisms listed in the drug monograph under
clinical indications for use) [43]. Only 9 antibi-
otics have an FDA-approved clinical indication
for use for Acinetobacter spp. (Table 2). Given the
complexity of clinical trial design and relative
infrequency of infections caused by Acinetobac-
ter spp., it is unlikely that new antimicrobials
will achieve indications for treatment of Acine-
tobacter. As of November 2017, Language in the
21st Century Cures Act allows the FDA to des-
ignate breakpoints set by standard setting
organizations, like CLSI, for use with cASTS.
CLSI can establish breakpoints independent of a
pharmaceutical sponsor, as occurred for colistin
in 2015 [44]. However, even if CLSI Acinetobacter
breakpoints are recognized by the FDA, it may
be years before a test is cleared for those
antibiotics on the automated cASTs that are
used by most laboratories (e.g., Vitek 2, Micro-
scan) [43], as development and marketing of
new cASTS typically takes 3–7 years. There is a
lack of prioritization for development of such
cASTs by the manufacturers [43].
It should be noted that tests are available for
Acinetobacter spp. outside the U.S, in countries
where manufacturers of cASTs are not subject to
FDA oversight. Furthermore, many laboratories
are able to perform susceptibility testing of
Acinetobacter spp. using CLSI breakpoints for
some drugs using FDA-cleared cASTs (Table 2).
This is because these devices were cleared prior
to 2007, the year FDA started enforcing regula-
tions requiring use of FDA breakpoints on
cASTs. However, the ability of these systems to
detect resistance mechanisms that have
emerged or become more common since 2007 is
unknown [43]. To further complicate matters,
several differences exist between CLSI and FDA
Acinetobacter breakpoints for the carbapenems
(Table 2). CLSI updated Acinetobacter carbapen-
ems breakpoints in 2012, in light of updated PK/
PD and clinical outcome data, but FDA has yet
to make adjustments. This is a critical issue, as
CLSI updates to breakpoints are designed to
Infect Dis Ther
detect clinically relevant resistance that might
be missed by historical (FDA) breakpoints.
PRACTICAL APPROACHES TO AST
OF ACINETOBACTER SPP.
The performance of available cASTs for
detecting resistance in Acinetobacter spp. is
unknown as almost no studies performed in
the past 10 years utilized current breakpoints
and contemporary isolates. Only one recent,
systematic evaluation of Vitek 2 as compared
to CLSI reference MICs has been performed,
including a small sample of 26 isolates of A.
baumannii. In this study, only 1 very major
error (i.e., false susceptibility) was noted, for
tobramycin, among 364 overall readings. In
Table 2 CLSI and FDA breakpoints for Acinetobacter spp
Antibiotic Susceptible breakpoints (lg/mL) FDA cleared cAST
CLSI FDA
Ampicillin-sulbactam B8/4 B8a All automated systems, Etest and disk






Imipenem B2 B4 All automated systems, Etest and disk
Meropenem B2 None
Polymyxin B B2 None None










Tigecyclinec None None None
a For Acinetobacter calcoaceticus only
b For A. baumannii only
c Many use a functional breakpoint of B2 ug/mL, but this has not been clinically validated
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contrast, between 11.5% and 30.7% minor
errors (i.e., intermediate MIC by Vitek2 and
susceptible by the reference method) were
noted for the b-lactam/b-lactamase inhibitor
combinations and cephems. This high inci-
dence of minor errors could potentially reduce
use of these drugs for treatment of AB, as
many clinicians view the intermediate and
resistant interpretations to be synonymous
[45]. Two additional studies evaluated the
performance of various methods for testing
activity of tetracyclines against CRAB [46, 47].
From these studies, it is apparent that Etest
(bioMerieux, Durham, NC, USA) yields ele-
vated MICs for minocycline, tigecycline and
doxycycline, again resulting in rates of false
non-susceptibility ranging from 15 to 37%.
This observation varied by manufacturer of
the Mueller–Hinton agar used, highlighting
the critical importance of cation content in
testing media for the tetracyclines, and in
particular tigecycline [46]. In contrast,
broth-based MIC methods, including Vitek 2
and Sensititre panels, performed well.
One option for testing antibiotics is off-line
testing using manual, research-use-only (RUO)
MIC tests (such as Sensititre panels made by
ThermoFisher, or in some cases Etest). This
approach allows interpretation of MICs by CLSI
breakpoints, or reporting of MICs without
interpretation if no breakpoint exists (for
example, for tigecycline). Laboratories that take
the RUO MIC approach should perform a veri-
fication study to ensure the RUO test yields
results that are accurate as compared to CLSI
reference broth microdilution method, and
include a disclaimer on patient reports indicat-
ing testing was performed using a device that is
not cleared by the FDA [43]. Performing a veri-
fication study for RUO products is critical, as
not all RUO tests perform acceptably for
detecting resistance, and may not yield repro-
ducible results. For example, RUO colistin disk
and Etest have been shown in several studies to
yield unacceptably high rates of false suscepti-
bility and false resistance, when compared to
CLSI broth microdilution [48], the only method
endorsed by CLSI and EUCAST for testing the
polymyxins [49].
ANTIBIOGRAM DATA
Cumulative institution-level antibiogram data
can be of significant value when evaluating
empiric treatment options prior to receipt of
antimicrobial susceptibility data. However, the
integrity of data used to generate the antibi-
ogram is crucial. The vast majority of laborato-
ries produce antibiograms from data generated
by cAST, which may be associated with bias
towards overcalling resistance. Additionally, the
number of isolates tested per antibiotic is
important. If a laboratory performs off-line
testing for a given agent (for example, minocy-
cline or colistin), it is likely that only more
resistant isolates would be tested against these
drugs. For example, the data presented in
Table 3 from one of our laboratories documents
54.4% of AB isolates were susceptible to mer-
openem in 2015 (n = 119 patients tested). In
this same year, only 4.3% of isolates were sus-
ceptible to doripenem (n = 65 patients tested),
because doripenem was tested using an off-line
panel and only for isolates that were not sus-
ceptible to one or more carbapenems. This
being said, knowledge of cumulative suscepti-
bility for more resistant isolates alone may be of
use—for example, when waiting for the labora-
tory to perform off-line testing for agents like
minocycline, tigecycline or colistin for the
patient with a carbapenem-resistant A. bau-
mannii infection (Table 3).
Generally speaking, if\30 isolates were tes-
ted in a given year, that species should not be
included in the cumulative antibiogram as it
makes the data less generalizable to future iso-
lates. For instance, in Table 3, we have calcu-
lated the antibiogram for all isolates of A.
baumannii recovered from all hospital inpa-
tients in our institution (n = 119 patients/iso-
lates) versus only those recovered from patients
in the ICU (n = 21 patients/isolates). While the
percent of isolates susceptible to colistin is very
similar (93.6% and 90.0%, respectively), the
95% confidence interval surrounding these data
is very broad—at the low end 74.9% versus
45.9% susceptible. While these data may still be
useful, it is important to report the number of
isolates included in antibiogram calculations.
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Alternatively, use of[1 year’s data can be con-
sidered, in particular if year-to-year susceptibil-
ity remains fairly stable. Finally, a combination
antibiogram can be constructed, which presents
data on the percent of isolates that are suscep-
tible to one or both agents in combination
(Table 4). This data can be very useful for
determining empirical treatment for patients
with, or suspected to have, infections caused by
Acinetobacter spp.
TREATMENT OF AB INFECTIONS
The most important facet of treatment for
patients infected with AB is early appropriate
antimicrobial therapy. Delays in administration
Table 3 Demonstration of the impact of number of isolates on conﬁdence for data and effect of inclusion of duplicate
isolates in the antibiogram
All isolates, all
patients (n 5 125)
1 isolate per patient,
ICU only (n5 22)
Meropenem resistant
isolates (n5 30)
Antibiotic %S 95% CI %S 95% CI %S
Ampicillin–sulbactam 53.6 42.9–64.3 50 25.5–74.5 0
Piperacillin–tazobactam 36 28.8–43.2 31.8 16.2–47.4 0
Ceftazidime 45.6 36.5–54.7 45.5 23.2–67.8 0
Cefepime 48.8 39.0–58.6 36.4 18.6–54.2 0
Imipenem 57.6 46.1–69.1 63.6 32.4–94.8 0
Meropenem 54.4 43.5–65.2 63.6 32.4–94.8 0
Amikacin 65.5 52.4–78.6 68.2 34.7–100 33.3
Gentamicin 53.6 42.9–64.3 54.5 27.8–81.2 11.5
Tobramycin 57.6 46.1–69.1 59.1 30.1–88.1 11.5
Ciproﬂoxacin 45.6 36.5–54.7 50 25.5–74.5 0
Trimethoprim–sulfamethoxazole 56 44.8–67.2 59.1 30.1–88.1 17.2
Colistin 93.6 74.9–100 90 45.9–100 92.8
Minocycline 60.9 48.7–73.1 57.1 29.1–85.1 50.0
Table 4 Example combination antibiogram for 89 isolates of AB isolated in 2015
Amikacin (67.4) Ciproﬂoxacin (50.6) Colistin [89]
Ampicillin–sulbactam (56.2) 67.4 59.5a 95.5a
Ceftazidime (50.6) 71.9a 55.1a 96.6a
Cefepime (52.8) 78.6a 57.3a 95.5a
Meropenem (59.6) 74.2a 59.5 95.5a
Data in parentheses indicate % of isolates susceptible to antimicrobial on their own, whereas other ﬁgures indicate % of
isolates that are susceptible to one or both of the antimicrobials
a Isolates for which a higher % is susceptible to the combination that either agent alone
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of antimicrobial therapy have been associated
with increased mortality, and time to appro-
priate therapy is the strongest modifiable risk
factor for poor outcomes of AB infections
[7, 50–52]. Randomized controlled trials are
lacking and the optimal antimicrobial treat-
ment for serious AB infections has not been
established. B-lactam antibiotics are the pre-
ferred antibiotics of choice for susceptible AB
infections [53]. Carbapenems have been regar-
ded as the treatment of choice for more resis-
tant isolates, although the incidence of CRAB is
increasing. Carbapenem resistance in AB has
been associated with three–fourfold higher
mortality during bacteremia and pneumonia,
primarily due to delays in time to effective
therapy and forcing the use of suboptimal
agents for definitive therapy [54–56]. Combi-
nation therapy is often recommended for these
infections on the premise that it may ensure at
least one agent is active in vitro, achieve cidal-
ity, improve clinical outcomes, and potentially
prevent the emergence of resistance.
Polymyxins
The efficacy of colistin (polymyxin E) in severe
infections due to AB has been demonstrated in
published reports [57–60], while data on poly-
myxin B are limited. In a prospective study of 35
episodes of VAP due to MDR AB, 21 patients
were treated with intravenous colistin
monotherapy as this was the only active agent
in vitro [57]. These patients were compared to
14 who received imipenem–cilistatin. The cure
rate was identical for both groups at 57% and
VAP-related mortality rates were also similar at
38% and 35.7% between colistin and imipe-
nem, respectively. Despite the scarcity of pub-
lished PK, PD, and clinical outcomes literature
on polymyxin B compared to colistin, poly-
myxin B possesses superior PK properties and
may be less nephrotoxic than colistin [61].
Regardless of which polymyxin is used, the
optimal dosing remains an enigma [62].
Recent in vitro pharmacodynamic evalua-
tions have suggested aggressive, ‘‘front-loaded’’
polymyxin B dosing regimens in combination
with carbapenems to combat MDR AB strains
and suppress the emergence of resistance [63]. A
retrospective study evaluated the safety and
efficacy of a colistin loading dose, high-dose
maintenance regimen in critically ill patients
with MDR Gram-negative pneumonia (68% of
whom had AB) and found no increase in clinical
cure or nephrotoxicity overall when compared
to cohort of patients receiving a lower dose
regimen without a loading dose [64]. Patients in
the high-dosing regimen group did have a sig-
nificantly higher rate of renal injury as assessed
by the risk, injury, failure, Loss of kidney func-
tion, and end-stage kidney disease criteria (10%
vs. 37%, P = 0.03). A recent review of the pub-
lished PK and clinical data regarding the utility
of a loading dose of colistin found that, despite
the theoretical PK benefit, data from random-
ized controlled trials are lacking while data from
observational studies do not support the use of
loading doses. To add to the confusion, the
latest in vitro hollow fiber infection model work
has demonstrated a paradoxical effect in which
higher polymyin B exposures dramatically
increased the isolation of resistant subpopula-
tions of AB that grew on plates containing
10 mg/L of polymyxin B [65]. These high
exposures also proliferated polymyxin-depen-
dent growth of AB. These experiments were
carried out under high bacterial inoculums and
without the benefit of the mammalian immune
system, so the clinical impact of these findings
remains to be determined, although this work
contributes to the notion that the polymyxins
should preferentially be given as part of a
combination therapy against AB.
Tetracyclines
Minocycline was first introduced in the 1960s
and maintains excellent in vitro activity against
AB, including isolates that are MDR, and has
been used successfully clinically in several small
case series. Minocycline is FDA approved for
infections due to Acinetobacter, both an intra-
venous and oral formulation are available for
use, and toxicity after short-term use remains
minimal. The parenteral minocycline product
was also reformulated and FDA approved under
the Qualified Infectious Disease Product by The
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Medicines Company in April 2015 [66]. This
reformulated product (previously RPX-602)
incorporates magnesium sulfate which allows
intravenous minocycline to be administered in
smaller volumes of fluid and may improve tol-
erability. Minocycline often retains antimicro-
bial activity even against AB strains resistant to
other tetracyclines and glycyclines, although
cross-resistance exists. It is important that
doxycycline not be used as a surrogate for
minocycline susceptibilities, as resistance rates
are significantly higher for doxycycline. In a
recent study of 107 CRAB isolates, minocycline
susceptibility rates were approximately 49%
higher than for doxycycline [67]. Several studies
have demonstrated the efficacy and safety of
minocycline for serious infections due to AB.
Minocycline has been used successfully in the
literature to treat VAP due to AB [68] and CRAB
[69]. The details of these studies have been
summarized by Ritchie et al. [70]. Doxycycline
retains some in vitro activity against AB but less
than that of minocycline and has been rarely
used for AB infections. Falagas et al. recently
reviewed the use of doxycycline and minocy-
cline for infections due to AB [71]. They inclu-
ded 10 retrospective studies comprising 156
patients, 65.4% of which had respiratory infec-
tions and 13% bacteremia. Clinical success was
achieved in 76.9% of patients with microbio-
logical eradication in 71.3%. Adverse events
were reported in only 1 of 88 cases. The utility
of intravenous minocycline in the modern era
of widespread bacterial resistance has also been
reviewed in detail by Colton et al. [72] and
Greig and Scott [73].
Tigecycline, a semisynthetic glycylcyline
derivative of minocycline, also maintains
excellent in vitro activity and has been used
successfully both alone and in combination
with colistin for AB infections [74]. Worldwide,
over 90% of AB isolates are susceptible to tige-
cycline [75, 76], although the data demon-
strating the clinical efficacy of tigecycline for
the treatment of AB infections are plagued by
high mortality rates, emergence of resistance
while on therapy, and frequent adverse events
[77–80]. A large, retrospective study examined
266 patients with XDR AB treated with tigecy-
cline alone or in combination and compared
them to 120 patients treated with
imipenem–cilastatin and sulbactam [81]. Thir-
ty-day mortality rates were high but similar
between the groups (44.7% vs. 46.7%). One
prospective multicenter Phase III trial compared
tigecycline to imipenem-cilastatin for patients
with VAP due to AB and found lower cure rates
in the tigecycline group (68% vs. 78%) [82].
Another retrospective study in ICU patients
with pneumonia due to MDR AB matched 84
patients receiving tigecycline to 84 receiving
colistin [83]. In this study, mortality was sig-
nificantly higher among patients receiving
tigecycline with a tigecycline MIC of[2 mg/L
(44% vs. 60.7%, P = 0.04). Several studies have
confirmed the relevance of the in vitro break-
point of C2 mg/L for tigecycline, demonstrating
higher mortality when tigecycline MICs
were C2 mg/L, even when tigecycline was used
as part of a combination regimen [83, 84]. Some
retrospective studies have demonstrated ade-
quate clinical and microbiologic outcomes with
tigecycline, although it was given as part of a
combination therapy in almost all cases
[85–87].
Ampicillin/Sulbactam
Sulbactam is a penicillanic acid sulfone b-lac-
tamase inhibitor with intrinsic in vitro activity
against AB, although MICs have shown a steady
increase over the last decade [76]. Ampi-
cillin–sulbactam has demonstrated similar
results to imipenem–cilastatin when treating
severe AB infections, including VAP, in small
case series, and was more effective than the
polymyxins in treating CRAB infections
[88–90]. It has demonstrated similar clinical and
microbiologic outcomes to colisin for MDR AB
VAP with less nephrotoxicity [91]. A recent
retrospective study from Taiwan reviewed
patients who received sulbactam alone or
ampicillin–sulbactam for the treatment of
pneumonia due to MDR AB [92]. Forty-five
patients received sulbactam compared to 125
who received ampicillin-sulbactam, although
79.8% of patients received combination therapy
primarily with a carbapenem (86.2%). Clinical
resolution of pneumonia occurred in 67.6% of
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patients with 69% demonstrating microbiolog-
ical eradication of AB from the airways. The
30-day mortality rate was 31.2%, and indepen-
dent predictors of clinical failure on multivari-
ate analysis included malignancy, bilateral
pneumonia, and shorter duration of therapy.
The latest retrospective observational study
examined patients with infections due to AB
treated with ampicillin–sulbactam or an alter-
native b-lactam for at least 72 h [93]. Of the 69
patients included, 33 received ampicillin–sul-
bactam and 36 received an alternative b-lactam
(primarily cefepime), and most had a respira-
tory source of infection. Approximately 20% of
patients received combination therapy with
colistin or tigeycline in the amnpicillin–sul-
bactam group. There were no significant differ-
ences in baseline demographics between the
groups including source of infection and sever-
ity of illness. Clinical cure was similar between
the groups (78.8% ampicillin–sulbactam vs
72.2% b-lactam, P = NS), along with length of
stay and mortality. Finally, a retrospective study
of 168 patients comparing tigecycline-based
versus sulbactam-based antimicrobial regimens
for the treatment of MDR AB pneumonia found
identical rates of clinical resolution (66.7%),
similar mortality, but a lower rate of microbio-
logical eradication in the tigecycline-based
group (26.2% vs. 63.5%, P\0.05) [94].
Similar to the polymyxins, ampicillin–sul-
bactam is likely most effective as part of a com-
bination regimen against AB, andoptimal dosing
remains unclear. Case series and observational
studies have demonstrated the efficacy of the
combination of ampicillin and sulbactam
against AB infections, including bacteremia
[88, 89, 95–97]. When the AB isolate is suscepti-
ble to ampicillin–sulbactam, the efficacy appears
to be comparable to other agents including car-
bapenems and polymyxins [90, 98]. Population
PK studies with Monte Carlo simulations have
demonstrated that, at typical ampicillin–sulbac-
tam doses of 3 g every 8 h, a probability of target
attainment (PTA) of 90 of 40% time above the
MIC can only be achieved using a 4-h infusion
and only for pathogens with an MIC B2 mg/L
[99]. Even at 12 g every 8 h as a 4-h infusion, a
PTAof 90%could only be achieved for pathogens
with an MIC B8 mg/L. Both of these doses are
likely inadequate, as in one study evaluating 121
isolates of AB, the MIC50 and MIC90 for ampi-
cillin sulbactam were 16/8 and 64/32 mg/L,
respectively [100]. In a clinical study, Betrosian
et al. randomized 27 patients with MDR AB VAP
to receive a total daily dose of either 27 or 36 g of
ampicillin–sulbactam divided every 8 h and
demonstrated no significant differences in clini-
cal improvement or bacteriologic success [101].
Importantly, there were nomajor adverse events
reported with this high-dosing scheme.
Aminoglycosides
Amikacin and tobramycin remain the most
active in vitro agents against AB among the
aminoglycosides. It is important to bemindful of
susceptibility differences based on the methods
used for testing against aminoglycosides against
AB [102], as significant discordance has been
reported. Aminoglycosides are falling out of
favor for the treatment of MDR Gram-negative
infections in general due to their high toxicity,
lack of efficacy, low tissue penetration, ambigu-
ous synergy, and the availability of more active,
less toxic agents [103, 104]. As a general rule,
aminoglycosides should not be used as
monotherapy for AB, as they demonstrate rapid
regrowth and persistence in vitro and poor clin-
ical outcomes [103, 105, 106], although one
small study from South Africa demonstrated
similar toxicity and clinical outcomes of tobra-
mycin compared to colistin when treating 32
patients with AB infections [107].
Rifampin
Rifampin has demonstrated activity against
MDR AB in vitro and in in vivo animal models,
although two randomized controlled trials
failed to show improved outcomes with the
addition of rifampin to colistin versus colistin
alone for infections due to AB [108, 109].
COMBINATION THERAPY
The wealth of in vitro data suggests that com-
bination therapy should be beneficial for the
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treatment of serious infections due to AB
[110, 111]. This includes utilizing carbapenems
in combination for CRAB, although clinical
reports have not always upheld the in vitro data
[112, 113]. The published results are not con-
clusive and may be disease state-dependent, as
combination therapy has demonstrated
improved rates of 14 day survival and microbi-
ological eradication for AB bacteremia [114],
but failed to show a benefit in patients with AB
sepsis [115]. The combination of colistin plus
rifampin for serious infections due to AB has
failed to demonstrate improved outcomes in
two clinical trials and a systematic review
[108, 109, 116]. A meta-analysis also concluded
that there was no clear benefit to combination
therapy for MDR, XDR, or PDR AB infections
[71].
The heterogeneity of combination therapies
used in the literature for AB infections is broad
but often includes colistin a part of the combi-
nation approach. Unfortunately, the vast
majority of the literature on combination ther-
apies with colistin is in vitro in nature [23].
Colistin combination therapy has shown
improved outcomes over colistin monotherapy
for patients with AB bacteremia, although no
specific combination proved better than
another [114]. A study of 101 patients in Spain
with MDR AB infections contrasts these results
and found no significant difference in 30-day
mortality between combination and
monotherapy [115]. A contemporary study
found no advantage of colistin combination
therapy for AB VAP in critically ill patients
[117]. The combination of colistin and gly-
copeptides has demonstrated synergy in vitro,
although two clinical studies are conflicting in
terms of clinical outcomes [118, 119]. A recently
published review examined the in vitro and
in vivo data regarding synergy of polymyxin
combinations and concluded that limitations in
current clinical studies (retrospective design,
small sample sizes) preclude the translation of
even well-executed in vitro experiments [120].
Two clinical trials are underway in the US and
Europe (NCT01732250, NCT01597973) com-
paring colistin monotherapy to colistin plus
meropenem, which may provide insight into
some of the ambiguity surrounding combina-
tion therapy for AB.
A recent study examined the correlation
between in vitro checkerboard and time-kill
synergy and clinical outcomes in patients
infected with XDR AB [121]. In this study, col-
istin with minocycline produced the highest
rate of synergy in vitro via checkerboard assay,
although only 6.6% of wells tested demon-
strated synergy which was equal to that of
doripenem–colistin–minocycline. Tigecy-
cline–colistin showed a 13.2% rate of antago-
nism while minocycline and colistin was
bactericidal against 100% of the 5 isolates tested
via time-kill. Patients who received a combina-
tion that demonstrated inhibition of growth
in vitro demonstrated improved microbiologi-
cal outcomes.
A retrospective study among critically ill
patients with MDR Gram-negative pneumonia,
the majority of whom had AB isolated,
demonstrated that colistin combination ther-
apy did not improve clinical cure but did sig-
nificantly improved microbiological cure (87%
vs. 35.5%, P\0.001) [122]. Tigeycycline was the
most common combination agent (51.2%) fol-
lowed by minocycline (12.2%). A post hoc
analysis of only patients with AB pneumonia
demonstrated no significant differences in
clinical cure, even after multivariate analysis,
but again demonstrated a higher rate of micro-
biological eradication for the 44 patients with
repeat cultures available.
A particularly interesting study examined
the outcomes of 101 critically ill patients with
infections due to AB (n = 83) or P. aeruginosa
(n = 18) who received either polymyxin B
monotherapy or polymyxin B in combination
with another agent that lacked in vitro activity
[123]. Combination therapy consisted primarily
of polymyxin B plus meropenem. The 30-day
mortality rate in the combination therapy
group was significantly lower than that of the
monotherapy group (42.4% vs. 67.6%, P = 0.03)
despite the lack of in vitro activity and combi-
nation therapy was independently associated
with lower 30-day mortality upon Cox propor-
tional hazards modeling along with normal
renal function. These differences remained after
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a propensity score adjustment was made to
account for the likelihood of receiving combi-
nation therapy. Given that all isolates but one
in this study were considered highly car-
bapenem-resistant (MIC[32 mg/L), it is likely
that some degree of synergy was occurring
in vivo and that there may be a benefit to
combination therapy regardless of susceptibility
profiles.
A prospective observational study of patients
with sepsis due to MDR AB who received active
mono- or combination therapy included 68
patients who received monotherapy and 33
who received combination therapy. A propen-
sity score was used to account for bias in
receiving combination therapy. The primary
infection was pneumonia, primarily VAP, and
colistin was used most often as monotherapy
(67.6%) followed by carbapenems (14.7%).
Colistin plus tigeycline was the most common
combination therapy, although this accounted
for only 27.3% of cases and the remaining
combination regimens were very heterogeneous
including carbapenem plus tigecycline. There
was no significant difference in all-cause 30-day




Controlling the morbidity and mortality asso-
ciated with AB requires a multifaceted approach
including early detection and identification,
strategies for patient risk factor identification,
infection control practices, and antimicrobial
stewardship surveillance and intervention.
A robust infection prevention program is
crucial to help curb the introduction and spread
of AB throughout a healthcare system. The pri-
mary goals of infection prevention as they relate
to AB are early recognition and containment.
Identifying high-risk patients and those colo-
nized with AB is vital, as previous colonization
with CRAB has been associated with infection
due to CRAB [124]. Despite the obvious advan-
tages of identifying patients who are colonized
with AB, particularly MDR AB, surveillance
culturing is not often implemented due to
significant logistic and practical challenges.
Surveillance cultures, especially from a single
site, have demonstrated low sensitivity and
require considerable labor and time commit-
ment from hospital and microbiology staff [10].
Specific microbiology laboratory media such as
CHROMagarTM can assist in this process by
rapidly and accurately identifying CRAB. The
CDC recommends active microbiological
surveillance for patients at high risk of colo-
nization with resistant Gram-negative organ-
isms and contact precautions. Cohorting,
improved hand hygiene, and enhanced envi-
ronmental cleaning have been successful at
reducing hospital infection rates and control-
ling outbreaks of AB [125–127].
A multinational task force on the manage-
ment and prevention of AB infections in the
ICU was recently established [128]. The goal of
the task force was to provide clinicians with
clear and practical recommendations to opti-
mize therapy and establish infection control
measures to eradicate AB. Among the processes
endorsed in the document, the group recom-
mends that AB should be routinely identified to
the species level by the clinical microbiology
laboratory in order to differentiate it from other
Acinetobacter spp. outside the AB group which
are only rarely known to cause human disease.
Additionally, AB bacteremia has been associated
with higher mortality than A. nosocomialis or A.
pitti bacteremia [129] and it is important to
correctly associate antibiotic resistant rates with
the appropriate species for epidemiologic
purposes.
Antimicrobial stewardship programs (ASPs)
play an important role in the management of
MDR AB infections. Among many important
interventions, ASPs can assist in the selection of
appropriate agents for the treatment of AB
based on the institutional antibiogram along
with an appropriate duration and deescalation
of therapy once susceptibility reports are
known. Limiting the use of broad spectrum
antimicrobial therapy is vitally important, par-
ticularly in the treatment of AB, as the use of
carbapenems has been linked with increased
incidence of CRAB [130], while restricting car-
pabenem use in the ICU has demonstrated a
twofold decrease in the incidence of CRAB
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[131]. ASPs can also support the implementa-
tion of rapid diagnostic testing (RDT) in order to
more quickly identify AB and its resistant
mechanisms in order to assist in infection con-
trol and optimize patient outcomes.
In the only published RDT and ASP inter-
vention study to incorporate non-blood iso-
lates, Wenzler et al. evaluated the use of
MALDI-TOF and ASP intervention in patients
with pneumonia and/or bacteremia due to AB
[132]. This study was unique in the fact that it
capitalized on the weakness of MALDI-TOF. By
selecting to study a specific pathogen that is
inherently MDR a majority of the time, the
identification of AB by MALDI-TOF allowed for
a rapid change in empiric antimicrobial therapy
prior to susceptibility results being available. In
this quasi-experimental study, 66 patients were
included in the pre-intervention group and 53
in the intervention group. The pre-intervention
group consisted of traditional microbiological
methods and standard existing stewardship
interventions, while the intervention group
utilized MALDI-TOF to identify AB and targeted
stewardship interventions to provide appropri-
ate antimicrobial therapy. Importantly, in this
study, patients who were already on effective
therapy (defined as any antimicrobial agent
with in vitro susceptibility) at the time of
MALDI-TOF identification were excluded in
order to assess the true impact of ASP inter-
vention. The combination of MALDI-TOF and
ASP in patients with pneumonia and/or bac-
teremia due to AB significantly reduced the time
to effective therapy by over 40 h and also sig-
nificantly improved clinical cure at 7 days in the
intervention group (34% vs. 15%, P = 0.016).
No significant differences in mortality or costs
were observed, although MALDI-TOF plus ASP
decreased the median infection-related length
of stay in the intervention group (13 vs
11 days).
An ASP-driven study also evaluated the
safety and effectiveness of minocycline for
patients with infections due to MDR AB [133].
The ASP program recommended the addition of
intravenous minocycline to formulary after an
examination of susceptibility rates revealed that
it was the third most susceptible agent behind
the polymyxins and tigecycline, and was active
against four of the six tigecycline-resistant
strains tested. After addition to formulary, the
ASP then conducted a retrospective evaluation
of the use of minocycline for patients with
serious MDR AB infections. A total of 55 criti-
cally ill patients (median APACHE II score 21)
were evaulated and the primary site of infection
was the respiratory tract in 58% of patients
followed by the bloodstream (18%). The
majority of infections were hospital-acquired
and clinical success was achieved in 73% of
patients with presumed or documented micro-
biological eradication in 78%. A quarter of the
patients died from their infection and the
median length of stay was 30 days. Only 3
patients received minocycline as monotherapy
in this study, while the most common agent
used in combination was colistin [19], but there
were 10 other heterogeneous combination reg-
imens used for the remaining 33 patients. There
were no documented adverse events related to
the use of minocycline.
PIPELINE AGENTS WITH ACTIVITY
AGAINST AB
There are several agents in the drug develop-
ment pipeline with promising in vitro activity
and innovative mechanisms of action, although
their place in therapy and effectiveness for
infections due to AB remains to be established.
Future non-antibacterial treatment options for
AB have been recently reviewed by Wong et al.
[53].
Bal30072
BAL30072 is a novel dihydroxypyridone
monobactam siderophore b-lactam that per-
meates Gram-negative bacteria via non-pori-
based routes involved in iron transport that
may allow it to escape resistance mechanisms
that compromise other b-lactams. BAL30072
has demonstrated activity in vitro against
OXA-23-producing AB, with 73% of 200 isolates
susceptible at 1 mg/L [134]. Against MDR AB, it
has demonstrated an MIC90 of 4 mg/L to iso-
lates with a meropenem MIC90 of [32 mg/L,
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while its in vitro susceptibility against CRAB is
comparable to tigecycline [135]. Importantly,
BAL30072 also demonstrated activity against
MBL-producing AB, including those strains
resistant to aztreonam [136]. This molecule has
also been shown to decrease meropenem MICs
two–eightfold and produce synergy in in vitro
time-kill assays, although in vivo efficacy was
suboptimal in a rat soft tissue infection model
[137]. Conversely in a murine septicemia
model, in vitro synergy of BAL30072 and mer-
openem did translate into improved efficacy
in vivo [138]. The addition of b-lactamase
inhibitors does not improve the activity of
BAL30072 against AB [139], but sub-MIC con-
centrations of colistin have been shown to
decrease the MIC fourfold in 82% of AB isolates.
Reduced susceptibility of AB to BAL30072
in vitro has been correlated to adeb expression
[140].
S-649266
Another novel parenteral siderophore cepha-
losporin antibiotic, S-649266, has been evalu-
ated in vitro against 104 strains of AB. This
compound demonstrated MIC50 and MIC90
values of 0.125 and 2 mg/L, respectively, com-
pared to[16 and[16 mg/L for meropenem. It
also demonstrated excellent activity against
carbapenemase-producing strains, including
MBL-producers [141]. A multicenter, random-
ized, open-label clinical study comparing
S-649266 to best available therapy for the
treatment of severe infections caused by car-
bapenem-resistant Gram-negative pathogens is
currently recruiting (NCT02714595).
Plazomicin
Plazomicin is a next-generation aminoglycoside
(‘‘neoglycoside’’) with extended activity over
other aminoglycosides against some Gram-pos-
itive and -negative pathogens. Against 407 AB
organisms isolated from 15 hospitals in New
York, plazomicin demonstrated MIC50 and
MIC90 values of 8 and 16 mg/L, respectively,
compared to 32–64 and[64 mg/L for all other
aminoglycosides tested [142]. Plazomicin
achieved synergy in combination with mer-
openem or imipenem against 69 imipenem-re-
sistant AB isolates from Spain. MIC90 values
were lower than the other aminoglcyosides,
carbapenems, and fosfomycin against CRAB,
but higher than colistin or tigecycline MICs
[143]. Overall, the in vitro activity of pla-
zomicin appears comparable to that of amika-
cin, and this drug will come with the same
clinical downsides as traditional aminoglyco-
sides, as discussed earlier.
Omadacycline
Omadacycline is a novel aminomethycycline
antibiotic similar to the tetracycline class but
with the ability to circumvent typical tetracy-
cline resistance mechanisms. It has demon-
strated MIC50 and MIC90 values of 0.025 and
4 mg/L, respectively, to AB [144] and excellent
activity against 5 NDM and 39 OXA-producing
isolates.
Eravacycline
Eravacycline is a novel synthetic fluorocycline
similar to the tetracyclines with broad
anti-Gram-positive and -negative activity [145].
Against tigecycline and carbapenem-resistant
AB from the UK, eravacycline MICs were
approximately twofold lower than that of tige-
cycline. Importantly, eravacycline retains
activity against most high-level minocy-
cline-resistant AB isolates.
SUMMARY
AB has become one of the most unpre-
dictable and difficult to treat pathogens over the
last 20 years, aided by its numerous mecha-
nisms of resistance. Empiric antibiotic selection
should be based on specific local susceptibility
data when available. Specific therapy of AB
infection is confounded by the lack of cAST
with limited breakpoint interpretations for AB.
The use of RUO testing methods can be prob-
lematic. Previously, carbapenems were regarded
as the drugs of choice for AB infections,
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although the incidence of CRAB is increasing.
Currently, the polymyxins have become
increasingly used, but concerns about dosing,
PK/PD, and toxicities have limited their uti-
lization. Among the tetracyclines, only
minocycline is included in automated cAST, has
FDA-cleared breakpoints, and has reliable
in vitro activity against AB. Combination ther-
apy for serious infections due to AB is reinforced
by in vitro data, although supporting clinical
data are inconclusive. Antimicrobial steward-
ship programs are essential to combat this
unpredictable pathogen through use of infec-
tion prevention, rapid diagnostics, antibi-
ogram-optimized treatment regimens, and
avoidance of carbapenem overuse. The antimi-
crobial development pipeline includes several
agents with in vitro activity against AB, but
their place in therapy and contribution to the
armamentarium against this pathogen remain
to be defined.
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